Drug Profile
Research programme: regulatory T cell-inducing DNA vaccines - Inovio Pharmaceuticals
Latest Information Update: 29 Mar 2023
Price :
$50
*
At a glance
- Originator Medical Center of Fudan University
- Developer Inovio Pharmaceuticals
- Class DNA vaccines
- Mechanism of Action Immunosuppressants; Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Alzheimer's disease; Multiple sclerosis
Most Recent Events
- 29 Mar 2023 Discontinued - Preclinical for Alzheimer's disease in USA (unspecified route)
- 29 Mar 2023 Discontinued - Preclinical for Multiple sclerosis in USA (unspecified route)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA